U.S. Markets closed

Mersana Therapeutics, Inc. (MRSN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.60-0.40 (-2.67%)
At close: 4:00PM EDT
14.62 +0.02 (0.17%)
After hours: 05:44PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.00
Open14.97
Bid14.13 x 1400
Ask15.75 x 1400
Day's Range14.52 - 15.06
52 Week Range13.79 - 29.09
Volume606,417
Avg. Volume599,050
Market Cap1.008B
Beta (5Y Monthly)2.48
PE Ratio (TTM)N/A
EPS (TTM)-1.43
Earnings DateMay 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.75
  • Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) CEO Will Probably Find It Hard To See A Huge Raise This Year
    Simply Wall St.

    Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) CEO Will Probably Find It Hard To See A Huge Raise This Year

    As many shareholders of Mersana Therapeutics, Inc. ( NASDAQ:MRSN ) will be aware, they have not made a gain on their...

  • New Strong Sell Stocks for May 28th
    Zacks

    New Strong Sell Stocks for May 28th

    ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021

  • Mersana Therapeutics to Present at Jefferies Virtual Healthcare Conference
    GlobeNewswire

    Mersana Therapeutics to Present at Jefferies Virtual Healthcare Conference

    CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:00 a.m. ET. A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy in patients with platinum-resistant ovarian cancer, as well as in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines. Contact:Investor & Media ContactSarah Carmody617-844-8577scarmody@mersana.com